Zacks Investment Research upgraded shares of Intec Pharma (NASDAQ:NTEC) from a sell rating to a hold rating in a report published on Tuesday.
According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “
A number of other research firms have also recently issued reports on NTEC. LADENBURG THALM/SH SH reiterated a buy rating and issued a $12.00 target price on shares of Intec Pharma in a research report on Tuesday, January 29th. ValuEngine upgraded Intec Pharma from a hold rating to a buy rating in a research report on Monday. HC Wainwright reiterated a buy rating and issued a $16.00 target price on shares of Intec Pharma in a research report on Monday, December 10th. BidaskClub cut Intec Pharma from a strong-buy rating to a buy rating in a research report on Thursday, December 20th. Finally, Oppenheimer set a $15.00 target price on Intec Pharma and gave the company a buy rating in a research report on Sunday, December 2nd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company has a consensus rating of Buy and an average price target of $11.96.
Shares of NASDAQ NTEC traded down $0.04 during mid-day trading on Tuesday, reaching $7.87. The company had a trading volume of 413 shares, compared to its average volume of 132,848. Intec Pharma has a one year low of $3.55 and a one year high of $8.78. The stock has a market capitalization of $259.69 million, a P/E ratio of -4.78 and a beta of 0.39.
Intec Pharma (NASDAQ:NTEC) last issued its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.28) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.03. Research analysts anticipate that Intec Pharma will post -1.31 earnings per share for the current year.
Large investors have recently added to or reduced their stakes in the company. Reilly Financial Advisors LLC bought a new stake in shares of Intec Pharma during the fourth quarter worth about $38,000. Renaissance Technologies LLC grew its holdings in shares of Intec Pharma by 484.3% during the second quarter. Renaissance Technologies LLC now owns 88,898 shares of the biotechnology company’s stock worth $391,000 after purchasing an additional 73,684 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Intec Pharma by 50.0% during the third quarter. PNC Financial Services Group Inc. now owns 75,000 shares of the biotechnology company’s stock worth $424,000 after purchasing an additional 25,000 shares during the last quarter. Laurion Capital Management LP bought a new stake in shares of Intec Pharma during the third quarter worth about $532,000. Finally, ARK Investment Management LLC bought a new stake in shares of Intec Pharma during the third quarter worth about $609,000. Institutional investors own 39.76% of the company’s stock.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Featured Story: How do buyers and sellers choose a strike price?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.